ABL Diagnostics S.A. logo

ABL Diagnostics S.A. (ABLD)

Market Closed
10 Aug, 15:30
XPAR XPAR
2. 42
-0.06
-2.4194%
46.04M Market Cap
- P/E Ratio
1.12% Div Yield
4,672 Volume
- Eps
2.48
Previous Close
Add Transaction
Day Range
2.4 2.58
Year Range
2.12 5
Want to track ABLD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

ABLD closed today lower at €2.42, a decrease of -2.4194% from yesterday's close, completing a monthly decrease of -18.2432% or -€0.54. Over the past 12 months, ABLD stock lost -19.8675%.
ABLD is not paying dividends to its shareholders.
ABL Diagnostics S.A. has completed 1 stock splits, with the recent split occurring on May 18, 2022.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on XPAR (EUR).

ABLD Chart

People also search for

Artea Bankas AB
5.3
-1.8519%
Uniti S.A.
1.38
0%
Crypto Blockchain Industries SA
0.1
+1.9802%
Innovative-RFK S.p.A.
1.85
-2.6316%
Wellness Resorts Socimi, S.A.
2.2
0%

ABL Diagnostics S.A. (ABLD) FAQ

What is the stock price today?

The current price is €2.42.

On which exchange is it traded?

ABL Diagnostics S.A. is listed on XPAR.

What is its stock symbol?

The ticker symbol is ABLD.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 1.12%.

What is its market cap?

As of today, the market cap is 46.04M.

Has ABL Diagnostics S.A. ever had a stock split?

ABL Diagnostics S.A. had 1 splits and the recent split was on May 18, 2022.

ABL Diagnostics S.A. Profile

Insurance Industry
Financials Sector
Mr. Ronan Boulme CEO
XPAR Exchange
FR001400AHX6 ISIN
France Country
20 Employees
3 Jul 2026 Last Dividend
18 May 2022 Last Split
- IPO Date

Overview

ABL Diagnostics Société anonyme, originally known as Etablissements Fauvet Girel, is a renowned provider of molecular biology assays and comprehensive solutions primarily used for molecular detection through polymerase chain reaction (PCR) and DNA sequencing technologies. With its headquarters located in Woippy, France, the company operates both domestically and internationally. It specializes in genotyping for a range of viruses, including SARS CoV-2 and HIV, through next-generation sequencing (NGS) and Sanger sequencing methods. In April 2022, it transitioned its name to ABL Diagnostics Société anonyme, reflecting its affiliation as a subsidiary with Advanced Biological Laboratories (ABL) S.A. ABL Diagnostics takes pride in serving a diverse clientele that encompasses academic clinical pathology labs, private reference labs, and research institutions, selling its products directly and through a vast distributor network.

Products and Services

The company's portfolio is vast, encompassing a variety of diagnostics and research solutions, which include:

  • Genotyping through NGS and Sanger Sequencing: Offers genotyping services for detecting and analyzing viruses such as HIV, SARS CoV-2, hepatitis-C, mycobacterium tuberculosis, and 16S RNA. This is crucial for identifying specific types and mutations of pathogens, enabling targeted treatment strategies.
  • Ultragene Assays for Viral Detection: Specializes in the detection of viruses like SARS CoV-2, dengue, and Zika virus using cutting-edge ultragene assays. These assays are essential in the rapid and accurate detection of viral infections, facilitating timely intervention.
  • Microbiological Specimen Transport and Collection Kits: Supplies a wide range of kits for the collection, preservation, and inactivation of RNA and saliva, surface collection, and wastewater collection. These kits are indispensable for ensuring the integrity of samples from collection to analysis.
  • Instrument and Consumables: Provides a comprehensive list of instruments and consumables necessary for molecular biology research, including DNA/RNA extraction systems, real-time PCR systems, liquid handling robots, NGS library preparation systems, and Sanger sequencing reagents. These tools are essential for conducting high-throughput and high-fidelity molecular analyses.
  • Digital Solutions: Offers digital solutions that encompass analysis software, data hosting, lab automation, Nadis, and SeqHepB. These digital platforms and tools are designed to enhance the efficiency and accuracy of data analysis and management in laboratory settings.

Contact Information

Address: 72c, rue de Thionville
Phone: 33 3 87 17 81 56